Stealth Peptides Inc.' Bendavia(TM) Recognized as One of Stealth Peptides Inc.'s Top 10 Cardiovascular and Metabolic Development Programs to Watch

BOSTON--(BUSINESS WIRE)--Stealth Peptides, a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with significant unmet medical needs, announced today that its lead clinical candidate, Bendavia™, a novel compound that targets the mitochondrion to treat ischemia reperfusion injury, was recognized as one of the “Top 10” cardiovascular and metabolic projects to watch by Windhover Information, a division of Elsevier Business Intelligence. Stealth presented an overview of Bendavia and its potential for treating cardio–renal diseases during Windhover’s recent Therapeutic Area Partnerships Conference in Boston, Massachusetts.